The 5 most-read breast cancer articles on AJMC.com this year included FDA approvals, emerging therapies for metastatic breast ...

LINKER-MM4 trial shows linvoseltamab monotherapy achieves a 79% overall response rate in newly diagnosed MM patients, with 92 ...

Tom Kim, MD, of Sound Long-Term Care Management, discusses how serious illness and care coordination set these ACO patients ...

The most-read coverage of the latest updates in acute myeloid leukemia (AML) for 2025 focused on the evolution of targeted ...

New research reveals teclistamab and daratumumab significantly enhance progression-free survival in multiple myeloma, ...

Menin inhibitors target the interaction between menin and the KMT2A complex, offering a breakthrough in treating acute ...

FLAMeS, a new convolutional neural network, enhances MS lesion segmentation accuracy using only T2-weighted FLAIR images, ...

Lerodalcibep-liga, a once-monthly PCSK9 inhibitor, significantly reduces LDL-C in hypercholesterolemia, including HeFH, with ...

Ryan Haumschild, PharmD, MS, MBA, introduces the faculty and sets the agenda to explore disease background, novel therapies, ...

These top 5 stories underscore how 2025 was a year of constant friction at the intersection of public health and political ...

Panelists discuss how schizophrenia typically evolves through distinct phases—from first-episode psychosis to chronic illness ...

Panelists discuss how relapse is one of the most significant challenges in schizophrenia management, often resulting in ...